Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px
Document › Details

Intrinsic Bioprobes Inc.. (3/31/09). "Press Release: Intrinsic Bioprobes Inc. Enters into a $1.27M Contract with the National Cancer Institute to Develop Multiplex Mass Spectrometric Immunoassays for Detection of Low Abundance Cancer Related Proteins". T

Region Region United States (USA)
Organisations Organisation Intrinsic Bioprobes Inc. (IBI)
  Group Thermo Fisher (Group)
  Organisation 2 National Cancer Institute (NCI) (US)
  Group United States (govt)
Products Product MSIA technology (mass spectrometric immunoassay)
  Product 2 proteomic marker (diagnostics)
Person Person Nedelkov, Dobrin (Intrinsic Bioprobes 201007 CEO)
     


Intrinsic Bioprobes Inc. today announced the start of a contract with the National Cancer Institute to develop effective technologies for accurate measurement of cancer related proteins and peptides that improve diagnostic capabilities by effectively discerning diseased from non-diseased states. The total cost of the two and a half years contract is $1,276,360, out of which $1,130,272 is Federal money provided by the NCI, and $146,088 is the contractor’s share provided by Intrinsic Bioprobes Inc. This contract is in support of NCI’s Clinical Proteomic Technologies for Cancer initiative to assess and apply proteomic technologies and data resources to solve critical problems in cancer research (http://proteomics.cancer.gov).

“The purpose of this contract is to stimulate the development of multiplex mass spectrometric immunoassay for the detection of low abundance cancer related proteins/peptides from bodily fluids” says Dobrin Nedelkov, Ph.D., the Scientific Director of Intrinsic Bioprobes. “The application of proteomics tools in clinical setting lags far behind their use in basic science and drug discovery. The multiplex mass spectrometric immunoassays will bridge that gap because they are highly specific and selective, have ultra-sensitive detection capabilities and broad dynamic range, and require limited sample preparation. The mass spectrometric aspect of the assays also enables singlestep detection of protein isoforms and their individual quantification, which is an important protein diversity aspect regularly overlooked in contemporary proteomics approaches”, adds Nedelkov.

Intrinsic Bioprobes Inc. is a privately held Biotechnology Company focused on developing mass spectrometry-based assays and platforms for rapid and sensitive protein biomarker analysis. The company's proprietary technologies consist of Mass Spectrometric Immunoassay (MSIATM), a high-performance immunoassay combining micro-scale immunoaffinity capture and mass spectrometry for high throughput analysis of proteins from complex biological matrices, and Bioreactive Mass Spectrometer Probes (BRPTM), devices for rapid, sensitive and accurate protein haracterization.

These root technologies are incorporated into the MASSAYTM System, a high throughput mass spectrometry platform for rapid proteome analysis. For more information about Intrinsic Bioprobes Inc., please visit http://www.intrinsicbio.com.

Contact: Intrinsic Bioprobes Inc.
Tel. (480) 804-1778
E-mail: info@intrinsicbio.com

   
Record changed: 2016-03-19

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Thermo Fisher (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px